dc.contributor.author | Kmiecik, Justyna | en_US |
dc.contributor.author | Gras Navarro, Andrea | en_US |
dc.contributor.author | Poli, Aurélie | en_US |
dc.contributor.author | Planaguma, Jesus | en_US |
dc.contributor.author | Zimmer, Jacques | en_US |
dc.contributor.author | Chekenya, Martha | en_US |
dc.date.accessioned | 2017-09-22T11:35:43Z | |
dc.date.available | 2017-09-22T11:35:43Z | |
dc.date.issued | 2014 | |
dc.Published | Kmiecik J, Gras Navarro A, Poli A, Planaguma J, Zimmer J, Chekenya M. Combining NK cells and mAb9.2.27 to combat NG2-dependent and anti-inflammatory signals in glioblastoma. Oncoimmunology. 2014;3:e27185 | eng |
dc.identifier.issn | 2162-402X | |
dc.identifier.uri | https://hdl.handle.net/1956/16717 | |
dc.description.abstract | Glioblastoma is a deadly brain cancer with limited treatment options. Targeting chondroitin sulfate proteoglycan 4 (CSPG4, best known as NG2) with the monoclonal antibody mAb9.2.27 and activated natural killer (NK) cells abrogated the tumor growth and prolonged the survival of glioblastoma-bearing animals by favoring the establishment of a pro-inflammatory microenvironment. The combination of NK cells and mAb9.2.27 recruited ED1+CCR2low macrophages that stimulated ED1+ED2lowMHCIIhigh microglial cells to exert robust cytotoxicity. Our findings demonstrate the therapeutic potential of targeting salient tumor associated-antigens. | en_US |
dc.language.iso | eng | eng |
dc.publisher | Taylor & Francis | eng |
dc.rights | Attribution CC BY-NC | eng |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/ | eng |
dc.subject | CNS immunosurveillance | eng |
dc.subject | CSPG4 | eng |
dc.subject | Glioblastoma | eng |
dc.subject | NK cells | eng |
dc.subject | passive immunotherapy | eng |
dc.title | Combining NK cells and mAb9.2.27 to combat NG2-dependent and anti-inflammatory signals in glioblastoma | en_US |
dc.type | Peer reviewed | |
dc.type | Journal article | |
dc.date.updated | 2017-08-24T08:35:34Z | |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2014 Landes Bioscience | |
dc.identifier.doi | https://doi.org/10.4161/onci.27185 | |
dc.identifier.cristin | 1151596 | |
dc.source.journal | Oncoimmunology | |
dc.subject.nsi | VDP::Medisinske fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Medisinsk immunologi: 716 | |
dc.subject.nsi | VDP::Midical sciences: 700::Basic medical, dental and veterinary sciences: 710::Medical immunology: 716 | |